RxDoctor Payments Data

Alexandra Koehn, NP

Nurse Practitioner · Blue Ash, OHNPI 1861672339

Payments from drug & device makers

$1,466in general payments, 2019–2025

Across 37 payments — averaging $39.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$364
  • Acadia Pharmaceuticals Inc$291
  • Neurocrine Biosciences, Inc.$255
  • Sun Pharmaceutical Industries Inc.$120
  • Avanir Pharmaceuticals, Inc.$120
  • Takeda Pharmaceuticals U.S.A., Inc.$116
  • plus $200 from 6 others

What the payments were for

  • Food & beverage$1,466100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,466 in reported general payments places this provider in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$81,967
Medicare patients
156
Services billed
1,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide44$35,409
EliquisApixaban115$33,054
Sevelamer Carbonate18$4,741
TrintellixVortioxetine Hydrobromide17$4,159
Pantoprazole Sodium80$3,884
FarxigaDapagliflozin Propanediol13$3,771
Lacosamide24$3,756
Clobazam13$3,517
Oxycodone Hcl134$3,363
Lorazepam147$3,182
Sucralfate23$3,062
Pregabalin48$2,094
Budesonide13$1,847
Tramadol Hcl136$1,734
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen73$1,719

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$15$35,40944 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$116$4,15917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Blue Ash

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →